Allon Therapeutics I (NPCUF) 0.0002 $NPCUF
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Merchants Bancshares IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:
MB Financial Inc.Corporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:
Lindsay CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population.
Lockheed Martin CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
The following issues have been halted by IIROC:
American Securities Completes Acquisition of Frontier Spinning Mills
PR Newswire - Thu Dec 19, 11:00AM CST
American Securities LLC, a leading U.S. private equity firm, today announced that, in partnership with management, it has completed the acquisition of Frontier Spinning Mills Holding Corp., a leading producer of cotton yarn for the knitting and weaving industries, from an affiliate of Sun Capital Partners, Inc. Financial terms of the transaction were not disclosed.
Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
PR Newswire - Tue Dec 03, 6:30AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board. Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company. His background also includes leadership roles with GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS).
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral
Paladin Labs Inc. Acquires Allon Therapeutics Inc.
Marketwire - Tue Jul 16, 3:31PM CDT
Paladin Labs Inc. (TSX: PLB) ("Paladin" and/or the "Company" , a leading Canadian specialty pharmaceutical company, and Allon Therapeutics Inc. (TSX: NPC) announced today that in accordance with the Order for Reorganization in Allon's proposal proceedings under the Bankruptcy and Insolvency Act (Canada) and under the Canada Business Corporations Act which have been previously announced, Paladin has become the sole shareholder of Allon.
IIROC Trade Halt - Allon Therapeutics Inc.
Newsfile Corp - Thu May 30, 7:23AM CDT
The following issues have been halted by IIROC:
Cognitive Impairment - Pipeline Review, H1 2013
M2 - Tue Apr 23, 5:08AM CDT
Research and Markets has announced the addition of the Cognitive Impairment - Pipeline Review, H1 2013 report to their offering. 'Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Cognitive Impairment Therapeutics Development - Albany Molecular Research, Inc. - Allon Therapeutics Inc. - Amgen Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - BIOPROJET SCR - Bio-Link - Bionomics Limited - Boehringer Ingelheim GmbH - Celon Pharma Sp. z o.o. - Chiesi Farmaceutici SpA - Dart NeuroScience LLC - Eli Lilly and Company - Envoy Therapeutics, Inc. - Evotec Aktiengesellschaft - Galenea Corp. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Merck & Co., Inc. - Mithridion, Inc. - Omeros Corporation - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - SeneXta Therapeutics SA - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Theratechnologies Inc. For more information visit Cognitive Impairment - Pipeline Review, H1 2013
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic
Allon provides shareholder update
CNW Group - Tue Feb 05, 5:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its previously announced strategic review has generated a number of different strategic alternatives and opportunities that are being actively evaluated. The Company is aggressively managing ongoing operating expenses. This strategic review process includes considering all reasonable options for exploiting Allon's assets as well as securing additional financing.
TSX Delisting Review - Allon Therapeutics Inc. (Symbol: NPC)
CNW Group - Tue Feb 05, 7:45AM CST
DELISTING REVIEW Allon Therapeutics Inc. (the "Company" - TSX is reviewing the Common Shares (Symbol: NPC) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process.
Allon director takes new role
CNW Group - Wed Jan 30, 4:30PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that Mr. Michael Aldridge, Director of the Company since June 2011, has resigned to accept a new professional responsibility in the biotech industry.
Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products
Allon cuts staff and administrative costs
CNW Group - Fri Dec 21, 3:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that, after the negative results in its pivotal davunetide study, it has implemented staff and administrative reductions.
Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:
Merchants Bancshares IncCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:
MB Financial Inc.Corporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:59PM CST
Trading resumes in:
Lindsay CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population.
Lockheed Martin CorporationCorporate Event Announcement Notice
Wall Street Horizon - Thu Dec 19, 7:58PM CST
The following issues have been halted by IIROC:
American Securities Completes Acquisition of Frontier Spinning Mills
PR Newswire - Thu Dec 19, 11:00AM CST
American Securities LLC, a leading U.S. private equity firm, today announced that, in partnership with management, it has completed the acquisition of Frontier Spinning Mills Holding Corp., a leading producer of cotton yarn for the knitting and weaving industries, from an affiliate of Sun Capital Partners, Inc. Financial terms of the transaction were not disclosed.
Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
PR Newswire - Tue Dec 03, 6:30AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board. Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company. His background also includes leadership roles with GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS). Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/93dth7/peripheral) has announced the addition of the "Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for peripheral neuropathy (sensory neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for peripheral neuropathy (sensory neuropathy). The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for peripheral neuropathy (sensory neuropathy). - A review of the peripheral neuropathy (sensory neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the peripheral neuropathy (sensory neuropathy) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Peripheral Neuropathy (Sensory Neuropathy) Overview Therapeutics Development An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned - Allon Therapeutics Inc - Neuren Pharmaceuticals Limited - NeurogesX, Inc - NsGene A/S For more information visit http://www.researchandmarkets.com/research/93dth7/peripheral
Paladin Labs Inc. Acquires Allon Therapeutics Inc.
Marketwire - Tue Jul 16, 3:31PM CDT
Paladin Labs Inc. (TSX: PLB) ("Paladin" and/or the "Company"
, a leading Canadian specialty pharmaceutical company, and Allon Therapeutics Inc. (TSX: NPC) announced today that in accordance with the Order for Reorganization in Allon's proposal proceedings under the Bankruptcy and Insolvency Act (Canada) and under the Canada Business Corporations Act which have been previously announced, Paladin has become the sole shareholder of Allon. IIROC Trade Halt - Allon Therapeutics Inc.
Newsfile Corp - Thu May 30, 7:23AM CDT
The following issues have been halted by IIROC:
Cognitive Impairment - Pipeline Review, H1 2013
M2 - Tue Apr 23, 5:08AM CDT
Research and Markets has announced the addition of the Cognitive Impairment - Pipeline Review, H1 2013 report to their offering. 'Cognitive Impairment - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Cognitive Impairment Therapeutics Development - Albany Molecular Research, Inc. - Allon Therapeutics Inc. - Amgen Inc. - AstraZeneca PLC - Avineuro Pharmaceuticals, Inc. - BIOPROJET SCR - Bio-Link - Bionomics Limited - Boehringer Ingelheim GmbH - Celon Pharma Sp. z o.o. - Chiesi Farmaceutici SpA - Dart NeuroScience LLC - Eli Lilly and Company - Envoy Therapeutics, Inc. - Evotec Aktiengesellschaft - Galenea Corp. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Merck & Co., Inc. - Mithridion, Inc. - Omeros Corporation - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - SeneXta Therapeutics SA - Suven Life Sciences Ltd. - Takeda Pharmaceutical Company Limited - Theratechnologies Inc. For more information visit Cognitive Impairment - Pipeline Review, H1 2013
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic
Allon provides shareholder update
CNW Group - Tue Feb 05, 5:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that its previously announced strategic review has generated a number of different strategic alternatives and opportunities that are being actively evaluated. The Company is aggressively managing ongoing operating expenses. This strategic review process includes considering all reasonable options for exploiting Allon's assets as well as securing additional financing.
TSX Delisting Review - Allon Therapeutics Inc. (Symbol: NPC)
CNW Group - Tue Feb 05, 7:45AM CST
DELISTING REVIEW Allon Therapeutics Inc. (the "Company"
- TSX is reviewing the Common Shares (Symbol: NPC) of the Company with respect to meeting the continued listing requirements. The Company has been granted 120 days in which to regain compliance with these requirements, pursuant to the Remedial Review Process. Allon director takes new role
CNW Group - Wed Jan 30, 4:30PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that Mr. Michael Aldridge, Director of the Company since June 2011, has resigned to accept a new professional responsibility in the biotech industry.
Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising Pipeline
M2 - Mon Jan 14, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/jbsd8v/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Dementia. - Coverage of products
Allon cuts staff and administrative costs
CNW Group - Fri Dec 21, 3:00PM CST
Allon Therapeutics Inc. (TSX: NPC) announced today that, after the negative results in its pivotal davunetide study, it has implemented staff and administrative reductions.
